Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
21 02 2020
Historique:
received: 30 10 2019
accepted: 11 12 2019
pubmed: 8 1 2020
medline: 22 12 2020
entrez: 8 1 2020
Statut: epublish

Résumé

Meropenem-vaborbactam is approved to treat hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), in Europe. Meropenem-vaborbactam activity was evaluated against 3,193

Identifiants

pubmed: 31907187
pii: AAC.02177-19
doi: 10.1128/AAC.02177-19
pmc: PMC7038313
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Boronic Acids 0
vaborbactam 1C75676F8V
Meropenem FV9J3JU8B1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 Carvalhaes et al.

Références

Infect Control Hosp Epidemiol. 2012 Mar;33(3):250-6
pubmed: 22314062
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
Antimicrob Agents Chemother. 2014;58(4):2322-8
pubmed: 24514083
J Intern Med. 2015 May;277(5):501-12
pubmed: 25556628
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288-1301
pubmed: 27573805
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 29038260
Clin Infect Dis. 2012 Oct;55(7):943-50
pubmed: 22752516
Infect Dis Ther. 2018 Dec;7(4):439-455
pubmed: 30270406
J Antimicrob Chemother. 2018 Nov 1;73(11):3053-3059
pubmed: 30060117
Antimicrob Agents Chemother. 2017 Mar 24;61(4):
pubmed: 28167547
Antimicrob Agents Chemother. 2013 Dec;57(12):6305-10
pubmed: 24100499
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29084745
MMWR Morb Mortal Wkly Rep. 2013 Mar 8;62(9):165-70
pubmed: 23466435
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28652234
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6326-32
pubmed: 27527080
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28848018
Antimicrob Agents Chemother. 2020 Jan 27;64(2):
pubmed: 31712207
Semin Respir Crit Care Med. 2015 Feb;36(1):74-84
pubmed: 25643272
Semin Respir Crit Care Med. 2017 Jun;38(3):301-310
pubmed: 28578554
BMC Infect Dis. 2014 Nov 28;14:135
pubmed: 25430700
Curr Opin Pulm Med. 2013 May;19(3):216-28
pubmed: 23524477
J Antimicrob Chemother. 2019 Jun 1;74(6):1595-1606
pubmed: 30843070
Eur Respir J. 2011 Jun;37(6):1332-9
pubmed: 20847075
J Med Chem. 2015 May 14;58(9):3682-92
pubmed: 25782055
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5454-8
pubmed: 27381386
Crit Care. 2016 Jan 29;20:19
pubmed: 26821535

Auteurs

Cecilia G Carvalhaes (CG)

JMI Laboratories, North Liberty, Iowa, USA cecilia-carvalhaes@jmilabs.com.

Dee Shortridge (D)

JMI Laboratories, North Liberty, Iowa, USA.

Helio S Sader (HS)

JMI Laboratories, North Liberty, Iowa, USA.

Mariana Castanheira (M)

JMI Laboratories, North Liberty, Iowa, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH